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SUMMARY 
 Nonocclusive mesenteric ischemia (NOMI) can develop in the absence of apparent 
anatomical obstruction of the mesenteric circulation in a variety of low flow states. The 
pathophysiology of NOMI is unexplored, the early diagnosis is challenging and the available 
treatments are of questionable effectiveness. In this respect, new experimental models are 
sought to clarify the exact pathomechanisms and new, effective therapeutic ways are needed 
to reduce the increasingly high mortality. Our first aim was to develop clinically relevant in 
vivo models to investigate the macro- and microcirculatory effects of NOMI. Also, we 
hypothesized the role of complement activation in the acute and subacute consequences of 
NOMI and our objectives were to characterize the effects of the inhibition of complement 
protein known as C5a during this condition. Acetyl-peptide-A (AcPepA) is an antisense-
homology box-derived peptide, which is capable to inhibit the C5a effects by binding directly 
to the anaphylatoxin. We hypothesized that the inhibition of C5a can decrease the intensity of 
inflammatory reactions and in parallel, to normalize the impaired mesenteric circulation. 
 Acute experimental pericardial tamponade (PT) was established in anesthetized 
minipigs, while partial aorta occlusion (PAO) was induced in rats to investigate the 
circulatory and inflammatory changes of NOMI in clinically relevant time frames. After the 
relief of PT, elevated levels of oxidative stress markers and inflammatory mediators were 
detected in association with the signs of diminished splanchnic microcirculation. 24 hours 
after PAO the macrocirculatory parameters improved significantly, while the intramural 
microcirculation was significantly impaired and accompanied by increased leukocyte 
infiltration. The in vivo histology confirmed the structural and microvascular damage of the 
mucosa. 
 In both animal models of NOMI, the administration of AcPepA moderated the 
hemodynamic changes, improved the intramural microcirculation, reduced the inflammatory 
activations and the histological signs of mucosal damage. In conclusion we can say that our 
newly developed animal models provide a cross section for events in the short and long time 
frames and proved to be suitable for the investigations of the pathophysiology of NOMI. The 
hemodynamic changes in the acute PT together with those observed after PAO suggest that 
complement activation plays central role in the early and late macro- and microcirculatory 
disturbances during NOMI. The results suggest that C5a inhibitor treatment influences 
favourably the hemodynamic effects and reduces the potentially harmful inflammatory 
activation after experimental NOMI as well. 
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1. INTRODUCTION 
1.1. Acute mesenteric ischemia 
 Acute mesenteric ischemia (AMI) is a serious, life-threatening condition with an 
approximately 50-70% mortality rate and considered as a vascular emergency with urgency 
that is comparable to myocardial infarction or apoplexy (1). Arrhythmia, ischemic heart 
disease, atherosclerosis, endocarditis and cardiomyopathies are among the most important risk 
factors for AMI (2). Transient decreases of the mesenteric blood flow may cause minimal 
mucosal lesions only, but if prolonged, splanchnic ischemia leads inevitably to transmural 
bowel necrosis and perforation (3). Besides, it is also recognized that inadequate intestinal 
blood supply can lead to secondary inflammatory activation, which reduces the integrity of 
the bowel wall in the long run (4). 
AMI is most often classified as occlusive or non-occlusive. The main causes of 
occlusive AMI are embolus or thrombus of the superior mesenteric artery (SMA) and 
mesenteric venous thrombosis (see details in Table 1). Non-occlusive mesenteric ischemia 
(NOMI), however, evolves in the absence of apparent anatomical obstruction of the 
mesenteric circulation in a variety of low flow states. Although it may account for 20-30% of 
AMI cases and different degrees of NOMI occur in many patients with unstable systemic 
circulatory conditions, including hemorrhagic shock (5), burn injury (6), pancreatitis (7) and 
the postoperative phase of cardiac and aortic surgery (8), it often remains undiagnosed (9).  
The mortality rate of NOMI is constantly high (approximately 50-70%), which 
highlights the need for prompt diagnosis and adequate treatment (10). Treatment is more 
likely to be effective, if started early after the onset of signs and symptoms, because the 
mortality increases exponentially after 6-8 hours (11). While the success rate of surgical 
treatments of occlusive AMI improved during the last decades, this has remained poor for 
NOMI (12). 
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Table 1. Clinical manifestation, risk factors and classification of acute mesenteric ischemia (cited from Karl E et. 
al 2012) 
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1.2. The pathomechanism of NOMI 
Almost any condition that can induce circulatory shock may precipitate NOMI. 
Circulatory shock is defined as a state of cellular and tissue hypoxia due to reduced oxygen 
transport and/or increased oxygen consumption or inadequate oxygen utilization. The shock 
can be divided into four main groups: cardiogenic, distributive, hypovolemic and obstructive. 
In cardiogenic shock, the intravascular volume is proper, but there is a decreased cardiac 
output (CO) caused by the failure of the heart to pump effectively. In distributive shock, the 
peripheral vascular resistance is reduced to a large extent, while hypovolemic shock is caused 
by the reduction of circulating blood volume. Obstructive shock is due to obstruction of the 
heart or major blood vessels. 
Information on the pathogenesis of NOMI is rather scarce, but it is assumed that the 
potentially life-threatening structural damage of the mucosa is associated with excessive and 
sustained splanchnic vasoconstriction (9). NOMI is frequently seen in obstructive shock states 
when an extramesenteric mechanical obstruction can be found in the underlying pathology. 
The major causes are tension pneumothorax, constrictive pericarditis or pericardial tamponade 
as a result of effusion of blood, pus, fluid, or gas into the pericardial sac (13). 
 Indeed, it has been shown that cardiac tamponade is accompanied by the release of 
different types of vasopressors (14) with a concomitant elevation of peripheral vascular 
resistance. The increased afterload may subsequently worsen the hypoperfusion of peripheral 
organs and results in an increased oxygen demand of the myocardium. The generalized 
hemodynamic impairment is characterized by a circulatory redistribution leading to regional 
hypoperfusion of the splanchnic area with NOMI and gastrointestinal (GI) mucosal damage 
(15, 16). 
The deficit in the delivery of intestinal blood provokes mesenteric vasoconstriction 
(17). Splanchnic hypoxia causes the activation of several endogenous vasoconstrictor 
mechanisms including the endothelin-1 (ET-1) system (18). ET-1 may compromise the 
intestinal mucosal circulation by increasing capillary permeability and reducing lymphatic 
flow leading to interstitial edema (19). Histamine is generally released in various types of 
tissue ischemia and increases the permeability of the capillaries. ET-1 can also cause 
histamine release by the degranulation of mast cells (20). High-mobility group box protein-1 
(HMGB-1), released passively by necrotic and damaged cells, has been recently identified as 
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an important signal for leukocyte recruitment (21). The microcirculatory dysfunction in 
NOMI seems to be mediated by the imbalance of vasoconstrictor and vasodilator molecules, 
such as ET-1 and nitric oxide (NO). This may also lead to increased leukocyte-endothelial cell 
interactions, no-reflow phenomenon with plugging of neutrophils, release of proinflammatory 
cytokines, oxidative stress and ultimately to hypoxic cell injury (22). Moreover, the activation 
of the complement cascade was described as well (23).  
Importantly, the reoxygenation can generate a more severe tissue injury than ischemia 
alone (24). During the reperfusion phase, the mesenteric blood flow decreases, the mesenteric 
vascular resistance increases, and the accumulation and free radical production capacity of the 
leukocytes rises (25). The elevated level of reactive oxygen species (ROS) plays a central role 
in this phase of the ischemia/reperfusion (IR) process (26, 27). Other endogenous compounds 
such as platelet‐activating factor (28), ET-1 (25), histamine (29), TNF‐α (30) and interleukins 
(31) play also an important role in the final tissue damage. More importantly, the IR can 
activate the immune system, including the complement system, via antigen‐independent 
inflammatory pathways (32).  
 
1.3. The role of the complement system in NOMI-caused hypoxia and inflammation 
 An increasing amount of indirect data suggests a central role for the innate immune 
system in the pathomechanism of NOMI. The complement system is made up of a number of 
distinct plasma proteins that react with each another in order to opsonize pathogens and 
induce a series of inflammatory responses that help to fight against infection. 
A number of complement proteins belong to the group of proteases that are themselves 
activated by proteolytic cleavage (33). Complement activation is known to occur through 
three different pathways: the classical, the alternative and the lectin pathways, involving 
proteins that mostly exist as inactive zymogens that are then sequentially cleaved and 
activated (Figure 1). All these pathways converge at C3 (which is the most abundant 
complement protein found in the blood), provoking the formation of the activation products, 
C3a, C3b, C5a and the membrane attack complex (C5b-9) (34). 
As a consequence of hypoxia and reoxygenation, significant amounts of anaphylatoxin 
C5a may be produced (35). The C5a fragment, a biologically active side-product of the 
complement cascade can induce smooth muscle contraction, chemotaxis, and the activation of 
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neutrophils (36) with the release of ROS and cytokines (37–40). C5a receptors are expressed 
not only on inflammatory leukocytes, but also on other cell types such as epithelial, 
endothelial, smooth muscle and other parenchymal cells of solid organs including liver, 
kidney, and lung. Furthermore, those C5aRs are extremely upregulated at an acute 
inflammatory state (41).  
Complement activation is further enhanced by the bacterial translocation through the 
hypoperfused intestinal mucosa (42), a process accompanied by the excessive release of ET-1 
(23, 43), which might contribute to a further impairment of the microcirculation due to its 
vasoconstrictor and pro-adhesive effects (44). Furthermore, the release of HMGB-1 is also 
directly mediated by C5a through C5a-like receptor 2 binding (C5L2) (45). HMGB-1 is an 
important factor of leukocyte recruitment, inducing the release of other proinflammatory 
cytokines (46).  
 
 
Figure 1. Schematic illustration of the activation of the C5a complement factor in the complement system (after 
Sarma JV et al. 2011). 
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1.4. Possibilities of C5a inhibition, the acetyl-peptide-A  
 Today, there are two main ways to have influence on C5a effects. One of the 
possibilities is the inhibition by means of anti-C5a antibodies and soluble receptors. However, 
these larger molecules are unstable, their production is expensive and biological side effects 
are also expected (47). The other alternative is the use of C5a receptor antagonists. 
Nevertheless, the usage of these antagonists has also lead to unintended consequences, mainly 
due to C5a receptor polymorphism (48).  
 A relatively new solution is the administration of acetyl-peptide-A (AcPepA). The 
acetylated N-terminal alanine (synthesized and purified (>95% purity) by Biologica, Nagoya, 
Japan) containing PepA (ASGAPAPGPAGPLRPMF) is an antisense homology box-derived 
peptide, which is capable of binding directly to C5a in its 37–53 amino acid region. It is 
important to note that the binding between the peptide and the C5a is not an antigen-antibody 
interaction.  
It has been shown that this anti-C5a peptide is more effective than C5a receptor 
inhibitors. AcPepA has proved to be highly effective in endotoxin shock pilot studies (49, 50). 
More importantly, the administration of AcPepA elevated the mean arterial pressure (MAP), 
did not affect the cardiac output, and caused a significant decrease in the heart rate (HR) in a 
previous study with experimental cardiac tamponade (51). 
 
1.5. Treatment options in NOMI 
 All patients with suspected AMI should undergo volume resuscitation and treatment 
with broad-spectrum antibiotics. The correction of any potential underlying mechanisms of 
AMI such as arrhythmias or congestive heart failure is necessary (52). Similarly to occlusive 
AMI, the conservative therapy of NOMI is non-specific and usually limited to hemodynamic 
support and the correction of biochemical alterations (9).  
 The first step in suspected NOMI is the catheter angiography (DSA, Class I 
recommendation, level B of evidence, according to The American College of Cardiology 
/American Heart Association guidelines), and the treatment of choice is the selective 
application of vasodilators into the SMA (PGE1 alprostadil in 20 μg bolus followed by a 
perfusor-directed 60-80 μg/24 hours doses; alternative method is PGI2 epoprostenol 5 to 6 
ng/kg/min and intravenous (iv) heparin 20 000 IU/24 hours). This protocol is intended to 
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interrupt the generalized vascular spasm. For patients with suspected NOMI who generally 
require catecholamine therapy, vasodilators are largely catabolized as they pass through the 
liver, thus no systemic effect or  consecutive neutralization of the effect of catecholamine is to 
be expected. Follow-up angiography is used to verify the efficiency of vasodilation. Surgery 
is required only when clinical evidence of peritonitis is present, or for intubated patients with 
secondary disruption to organ function. It is indicated only for the resection of irreversibly 
damaged portions of the intestines (11). 
 Non-surgical management is however, always challenging and precarious, and no 
vasodilator agent or therapy has gained widespread use so far to prevent the intestinal barrier 
dysfunction and the subsequent development of transmural gangrene. 
 
1.6. Animal models of NOMI 
 The consequences of experimental NOMI were investigated in several large animal 
models. In these cases NOMI is most often induced by pericardial tamponade (PT) (53–57). 
In other studies, mechanical occlusion of the SMA, noradrenalin infusion into the mesenteric 
circulation (17) or iv digoxin (55) were used. In these studies the short-term consequences of 
NOMI can be followed, nevertheless, the long-term macro- and microcirculatory 
consequences of NOMI-induced changes are still unknown.  
 In large animal PT models the tamponade is induced by filling of the pericardial sack 
with various fluids such as blood, saline or dextran (58–65). Previously, experimental PT 
models have been developed by our research group as well (14, 51). In these studies, PT is 
reproducibly leads to a decline in CO and a significant increase in HR. After relief of the 
tamponade, a significantly lower MAP and long-lasting impairment of the venous return are 
observed, while the CO and HR return to normal levels. Briefly, the deterioration of 
macrohemodynamics after PT is fairly well described, but the splanchnic microcirculatory 
and inflammatory changes and the long time consequences of NOMI are still unexplored (51).  
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2. MAIN GOALS 
 
 We hypothesized that experimental PT offers an opportunity to study the 
pathophysiology of NOMI. Our primary aim was to characterize the effects of PT on 
the intestinal microcirculatory alterations and inflammatory response in a large animal 
model. 
 We hypothesized that the inhibition of complement component C5a generation would 
suggest a plausible way to influence the potentially detrimental consequences of 
NOMI. The aim was to investigate the acute effects of complement C5a inhibitor 
treatment on NOMI-caused microcirculatory and inflammatory complications. 
 Our next aim was to develop a reliable rodent model of NOMI of extramesenteric 
origin and thus to investigate the major components of local and systemic circulatory 
reactions. We hypothesized that PAO in rodents leads to an established low-flow 
condition in the splanchnic area, and this would suggest a plausible way to investigate 
the pathophysiology of NOMI. Using this new model we decided to characterize the 
macro- and microcirculatory changes and inflammatory response 24 hours after the 
initial insult. 
 Our aim was to investigate the subsequent effects of AcPepA treatment on NOMI-
induced macro- and microcirculatory changes and inflammatory response so as to 
provide relevant information on the effects of C5a inhibitor therapy in a clinically 
relevant time frame. 
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3. MATERIAL AND METHODS 
3.1. Animals 
 The experiments were performed according to the National Institutes of Health 
guidelines and EU directive 2010/63 for the protection of animals used for scientific purposes 
and the study was approved by the Ethical Committee for the Protection of Animals in 
Scientific Research at the University of Szeged (number of approval: V/148/2013).  
 In Study I inbred Vietnamese mini pigs of both sexes (n=19, weighing 24±3 kg) were 
used. The experiments of Study II and Study III were performed on male Sprague-Dawley rats 
(n=31, average weight 350 g). 
 
3.2. Experimental protocol in Study I 
 The surgical interventions were carried out in minipigs during continuous infusion of 
propofol (50 μL/min/kg iv; 6 mg/kg/hr). Anesthesia was induced by a mixture of ketamine (20 
mg/kg) and xylazine (2 mg/kg) intramuscularly (im). After endotracheal intubation, the 
animals were mechanically ventilated with the tidal volume set at 9±2 mL/kg, and the 
respiratory rate was adjusted to maintain the end-tidal pressure of carbon dioxide and partial 
pressure of carbon dioxide in the range 35 to 45 mmHg. Positive end-expiratory pressure was 
not applied during the tamponade. The animals were placed in a supine position on a heating 
pad for maintenance of the body temperature between 36°C and 37°C and received an 
infusion of Ringer’s lactate solution at a rate of 10 mL/kg/hr during the experiments. The 
right femoral artery and jugular vein were cannulated for the measurement of MAP and CO 
by thermodilution method (PICCO Catheters; PULSION Medical Systems, Munich, 
Germany) and for fluid or drug administration, respectively. After a midline abdominal 
incision, the root of the SMA was dissected free. An ultrasonic flow probe (Transonic 
Systems, Ithaca, New York, USA) was placed around the exposed SMA to measure the 
mesenteric blood flow. In all protocols, the animals were monitored continuously, arterial 
blood gases were checked regularly (Cobas b121; Roche, Vienna, Austria), and a period of 30 
minute was allowed for recovery from surgery. 
 The animals were randomly allocated to one of the three experimental groups. Group 1 
(n = 6) served as sham-operated control, with the same time frame and sampling as in groups 
2 (n=7) and 3 (n=6), but without the induction of a cardiac tamponade. Left lateral 
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thoracotomy was performed in all groups, and in the cardiac tamponade groups, a cannula 
was fixed in the pericardial cavity. PT was induced for 60 minutes by intrapericardial 
administration of colloid solution, while the MAP was kept between 40 and 45 mmHg. After 
this period, the fluid was removed from the pericardial sac and the animals were monitored 
for 180 minutes following tamponade. Group 3 was treated by AcPepA (a single 
administration of 4 mg/kg in 5 mL saline iv into the jugular vein in a 5-min infusion) after the 
45
th
 minute of cardiac tamponade (the beginning of tamponade denotes 0 minute). Vehicle 
(saline) administration was applied in groups 1 and 2 with the same protocol. Peripheral blood 
samples were taken at baseline, after 75 and 150 minutes, and at the end of the observation 
period (240 minutes) to detect the levels of HMGB-1, big-endothelin (big-ET), and whole 
blood superoxide production. Small intestine tissue biopsies were taken at the end of the 
experiments for measurement of myeloperoxidase (MPO) activity. 
 
3.3. Experimental protocol in Study II  
 After intraperitoneal (ip) sodium pentobarbital anesthesia (50 mg/kg), the rats were 
placed in a supine position on heating pads. Tracheostomy was performed to facilitate 
spontaneous breathing, and the right jugular vein was cannulated by PE50 tubing for drug 
administration and Ringer-lactate infusion (10 mL/kg/hr). The left carotid artery and the left 
femoral artery were cannulated for MAP and HR measurements. A catheter equipped with 
thermistor-tip (PTH-01; Experimetria Ltd., Budapest, Hungary) was positioned into the 
ascending aorta through the right carotid artery for CO measurements, using thermodilution 
technique (SPEL Advanced Cardiosys 1.4, Experimetria Ltd, Budapest, Hungary). After a 
midline abdominal incision, the proximal part of the abdominal aorta was dissected free 
between the diaphragm and the origin of the SMA and a silicone tourniquet catheter was 
positioned around the vessel. An ultrasonic flow-probe was placed around the SMA (1RS; 
Transonic Systems Inc., Ithaca, New York, USA) to measure the flow in SMA. In each group, 
baseline macrohemodynamic parameters (MAP, CO, SMA flow) were recorded after a 30-
minute recovery period. Hemodynamic baseline measurements were taken, in 30 minute after 
the induction of PAO, before the relief of PAO, at 90 and at 120 minutes. 
 The animals were randomly divided into two groups. Group 1 (n=7) underwent a 1 
hour partial occlusion of the abdominal aorta induced by controlled tightening of the 
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tourniquet.  The goal was to keep MAP in the femoral artery continuously between 30 and 40 
mmHg. MAP, CO and SMA flow were recorded at baseline, in 30 minute after the induction 
of PAO, before the relief of PAO, at 90 and at 120 minutes. Differences in MAP between the 
femoral (MAPF) and the carotid arteries (MAPC), i.e. above and under the site of PAO, were 
recorded. Group 2 (n=6) served as sham operated control. 
 
3.4. Experimental protocol in Study III 
 The rats were placed in a supine position on heating pads and the left femoral artery 
was cannulated for recording of MAP and HR. After a midline abdominal incision, the 
proximal part of the abdominal aorta was dissected free between the diaphragm and the origin 
of the SMA and a silicone tourniquet catheter was positioned around the vessel. A Ringer-
lactate infusion (10 mL/kg/hr) was administered ip throughout the experiments. The baseline 
variables were determined during a 30-minute control period. 
Group 1 (n=8) served as the sham operated control group, while in group 2 (n=8) and 
group 3 (n=9), PAO was induced for 1 hour by controlled tightening of the tourniquet. The 
goal was to maintain MAP in the femoral artery continuously between 30 and 40 mmHg. In 
groups 1 and 2 the vehicle for AcPepA (infusion of 1 mL saline iv for 5 minutes) was injected 
into the tail vein, while in group 3 the injection of AcPepA (4 mg/kg in 1 mL saline iv) into 
the tail vein started 15 minute prior to the end of PAO. The animals were observed for 90 
minutes, the beginning of PAO denotes 0 min. MAP and HR were recorded 4 times (at 
baseline, at 30 minute after the induction of PAO, before the relief of PAO and 30 minute 
after the end of PAO). In each group, intravital videomicroscopy was performed in the 
baseline condition to examine the microcirculation of the serosa of the ileum 5 cm proximally 
from the cecum (see later). After the observation period, the femoral catheter was carefully 
removed, the wounds were closed and the animals recovered. In case of any signs of hind 
limb ischemia, the experiments were terminated and the animals were excluded from the 
study (n=3).  
 24 hours after surgery the animals were re-anesthetized (50 mg/kg ip sodium 
pentobarbital), tracheostomy was performed to facilitate spontaneous breathing, and the right 
jugular vein was cannulated with PE50 tubing for drug administration and Ringer-lactate 
infusion (10 mL/kg/hr iv). The left common carotid artery was cannulated by PE50 tubing for 
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MAP and HR measurements. A thermistor-tip catheter (PTH-01; Experimetria Ltd., Budapest, 
Hungary) was positioned into the ascending aorta through the right common carotid artery for 
CO measurements, using a thermodilution technique with a computer program (SPEL 
Advanced Cardiosys 1.4, Experimetria Ltd, Budapest, Hungary). The abdominal wound was 
reopened and an ultrasonic flow-probe was placed around the exposed SMA (1RS; Transonic 
Systems Inc., Ithaca, New York, USA) to measure the flow of the mesenteric artery. In each 
group, macrohemodynamic parameters were recorded after a 30-minute recovery period and 
intravital videomicroscopy was performed to examine the microcirculation of the ileal mucosa 
5cm proximally from the cecum. Through another incision, fluorescence confocal laser 
scanning endomicroscopy (CLSEM) was used for in vivo histological investigation. At the 
end of the experiments, blood samples were taken from the inferior caval vein for 
determination of plasma TNF-α, HMGB-1 and ET-1 levels. Tissue samples were taken from 
the ileum for conventional histological examinations and detection of leukocyte accumulation, 
and then the animals were sacrificed by an overdose of pentobarbital. 
 
3.5. Measurements  
3.5.1. Hemodynamic measurements 
 In Study I, central venous pressure (CVP) and blood flow signals were monitored 
continuously and registered with a computerized data acquisition system (SPELL Haemosys; 
Experimetria, Budapest, Hungary). The MAP, CO, and HR were measured with the PICCO 
Plus monitoring system (PULSION Medical Systems; Munich, Germany). 
 In Study II and III, pressure signals (BPR-02 transducer; Experimetria Ltd, Budapest, 
Hungary) and SMA flow signals (T206 Animal Research Flowmeter; Transonic Systems Inc., 
Ithaca, New York, USA) were measured continuously and registered also with a 
computerized data-acquisition system. 
 
3.5.2. Intravital videomicroscopy of the microcirculation 
 An intravital orthogonal polarization spectral imaging technique (Cytoscan A/R; 
Cytometrics, Philadelphia, PA) was used for non-invasive visualization of the mucosal 
microcirculation of the small intestine. This technique utilizes reflected polarized light at the 
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wavelength of the isosbestic point of oxy- and deoxyhemoglobin (548 nm). As polarization is 
preserved in reflection, only photons scattered from a depth of 200 to 300 μm contribute to 
image formation. A ×10 objective was placed onto the serosal surface of the ascending colon, 
and microscopic images were recorded by a S-VHS video recorder 1 (Panasonic AG-TL 700; 
Matsushita Electric Ind, Osaka, Japan). Quantitative assessment of the microcirculatory 
parameters was accomplished off-line by frame-to-frame analysis of the videotaped images. 
Red blood cell velocity (RBCV, μm/s) changes in the postcapillary venules were determined 
in three separate fields by means of a computer-assisted image analysis system (IVM Pictron, 
Budapest, Hungary). All microcirculatory evaluations were performed by the same 
investigators (MN and GV). 
  
3.5.3. Plasma HMGB-1, big-ET-1, ET-1, TNF-α and histamine measurements 
 In Study I, four ml blood samples were drawn from the jugular vein into chilled 
polypropylene tubes containing EDTA (1 mg/mL) at baseline, after 75 and 150 min, and at 
the end of the observation period (240 min). The blood samples were centrifuged at 1,200 g 
for 10 min at 4 °C. The plasma samples were afterwards collected and stored at -70°C until 
assay. The plasma concentration of HMGB-1 was measured with a commercially available 
HMGB-1 ELISA kit (Shino-Test, Kanagawa, Japan). Plasma levels of big-ET, a 38-amino 
acid precursor protein of ET-1, were measured with a commercially available kit (Biochemica 
Hungaria Kft., Budapest, Hungary). Plasma histamine concentrations were determined  with a 
commercially available enzyme-linked immunoassay (Quantikine ultrasensitive EIA kit for 
histamine; Biomedica Hungaria Kft, Budapest, Hungary). 
 In Study II and III, blood samples (0.5 mL) were taken from the inferior caval vein 
into precooled, heparizined (100 U/mL) polypropylene tubes, and centrifuged at 1,000 g at 4 
°C for 30 min and then stored at -70 °C until assay. Plasma TNF-α concentration was 
determined in duplicate by means of a commercially available enzyme-linked immunosorbent 
assay (Quantikine ultrasensitive ELISA kit for rat TNF-α; Biomedica Hungaria Kft, Budapest, 
Hungary). The plasma level of HMGB-1 was measured with a commercially available 
HMGB-1 ELISA kit. Concentrations of ET-1 in the plasma were examined with a 
commercially available kit (Biochemica Hungaria Kft., Budapest, Hungary). 
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3.5.4. MPO activity 
 The activity of MPO, a marker of neutrophil activation, was determined in ileal biopsy 
samples according to the method of Kuebler et al (66). Briefly, a reaction mixture containing 
50-mM K3PO4 buffer (pH 6.0), 2 mM 3,3′,5,5′-tetramethylbenzidine (dissolved in DMSO) 
and 100 μL of undiluted plasma sample was incubated for 5 min at 37°C. The reaction was 
started with 0.6 mM hydrogen peroxide (dissolved in 0.75 mL K3PO4 buffer) and was stopped 
after 5 min with 0.2 mL of H2SO4 (2 M), and the hydrogen peroxide–dependent oxidation of 
tetramethylbenzidine was detected by a spectrophotometer at 450 nm (UV-1601 
Spectrophotometer; Shimadzu, Kyoto, Japan). MPO levels were calculated via a calibration 
curve prepared with a MPO standard (Sigma-Aldrich GmbH, Munich, Germany). To detect 
the tissue MPO activity, ileal samples were homogenized with Tris-HCl buffer (0.1 M, pH 
7.4) containing 0.1 mM phenylmethylsulfonyl fluoride to block tissue proteases and then 
centrifuged at 4°C for 20 min at 24,000 g. The MPO activities of the samples were measured 
as described above, and the data were referred to the protein content. 
  
3.5.5. Whole blood superoxide production 
 For the whole blood superoxide production measurements, the chemiluminometric 
method of Zimmermann et al. (67) was used. During the measurements, 10 μL of whole blood 
was added to 1-mL Hank’s solution (PAA Cell Culture, Westborough, MA) and the mixture 
was kept at 37°C until assay. The chemiluminometric response was measured with a Lumat 
LB9507 luminometer (Berthold, Wildbad, Germany) during a 30-min period after the addition 
of 100 μL of lucigenin. 
 
3.5.6. Histological investigation of  leukocyte infiltration in tissues 
 Full-thickness ileal biopsies taken at the end of the experiments were analysed in each 
group. The tissue was fixed in 6% buffered formalin, embedded in paraffin, cut into 4-μm-
thick sections and stained with hematoxylin and eosin. The infiltration of leukocytes was 
detected and the number of leukocytes was counted in at least 20 fields of view at an original 
magnification of 400x. 
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3.5.7. In vivo detection of structural and microvascular damage of the mucosa – 
fluorescence CLSEM 
 The extent of microvascular damage of the terminal ileum was evaluated by 
fluorescence CLSEM (Five1; Optiscan Pty. Ltd., Melbourne, Victoria, Australia) developed 
for in vivo histology. Records were taken on day 2 for the observation of the effects of C5a 
inhibitor treatment. The mucosal surface of the terminal ileum (5 cm proximal to the cecum) 
was surgically exposed and laid flat for examination.  
 The microvascular structure was recorded after the iv administration of 0.3 ml of 
fluorescein isothiocyanate-dextran (FITC-dextran 150 kDa, 20 mg/ml solution dissolved in 
saline, Sigma-Aldrich Inc, St. Louis, MO, USA). The objective lens of the device was placed 
onto the mucosal surface of the ileum, and confocal imaging was performed 5 min after dye 
administration (1 scan/image, 1024 x 1024 pixels and 475 x 475 μm per image).  
 The injury of mucosal architecture was examined following topical application of the 
fluorescent dye acriflavin (Sigma-Aldrich Inc, St. Louis, MO, USA). The surplus dye was 
washed off the mucosal surface of the ileum with saline 2 min before imaging. Non-
overlapping fields of active areas of PAO were compared to the samples of AcPepA-treated 
or control groups by using a semiquantitative scoring system with the following criteria: I. the 
structure of the microvessels (0 = normal, 1 = dye extravasation, but the vessel structure is 
recognizable, 2 = destruction, and the vessel structure is unrecognizable); II. denudation of 
villi (0 = no denudation, 1 = at least one area per field of view, 2 = more than one area 
without a recognizable villi structure per field of view; III. edema (0 = no edema, 1 = 
moderate epithelial swelling, 2 = severe edema); IV. shedding cells (0 = normal, clearly, well-
defined villi structure without shedding cells , 1 = some shedding cells; less than 30 cells per 
field of view, 2 = shedding cells, more than 30 cells per field of view, 3 = severe debris); V. 
epithelial gap (0 = no gap, 1 = number of gaps, less than 5 per villi, 2 = number of gaps, more 
than 5 per villi); VI. longitudinal fissure on villi (0 = no fissure, 1 = presence of fissure). The 
analysis was performed twice, separately, by two investigators (MN and GV). 
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3.5.8. Statistical analysis 
 Data analysis was performed with a statistical software package (SigmaStat for 
Windows; Jandel Scientific, Erkrath, Germany). Friedman test for repeated-measures analysis 
of variance on ranks was applied within groups. Time-dependent differences from the 
baseline for each group were assessed by Dunn’s method, and differences between groups 
were analyzed by Kruskal-Wallis one-way analysis of variance on ranks, followed by Dunn’s 
method for pairwise multiple comparison. Differences between groups in the Study II were 
analysed by Mann-Whitney test, followed by Dunn's method for pairwise multiple comparison. In 
the figures, median values and 25
th
 and 75
th
 percentiles are given; p values of less than 0.05 
were considered as significant. 
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4. RESULTS 
4.1. Hemodynamics 
4.1.1. Acute changes in hemodynamics in Study I 
 A significant decrease in SMA flow indicated redistribution of the mesenteric 
circulation during the tamponade. After the removal of the pericardial fluid, the SMA flow 
returned to the control values. Administration of AcPepA after 45 min of cardiac tamponade 
resulted in a significant elevation of the SMA flow in the post-tamponade period (Figure 2A). 
 A heterogeneous, oscillating microcirculation was present in the small intestinal 
mucosa in all groups, and therefore, the weighted average of RBCV was calculated. This was 
based on the duration of the fast and slow flow periods and the RBCV during the respective 
phases, as reported previously (68). The RBCV during the fast flow periods showed no 
change in the sham-operated group, but at the end of the cardiac tamponade, a significant 
decrease from the baseline was observed in the group where cardiac tamponade was not used  
(Figure 2B). By the end of the post-tamponade phase, in the AcPepA-treated group, it was 
significantly increased regarding the baseline level and also relative to the non-treated group 
(cardiac tamponade group: M = 641.3; p25 = 584.5; p75 = 684.7 μm/s vs AcPepA group: M = 
1,031.3; p25 = 935.3; p75 = 1108.3 μm/s). The duration of the slow flow period in the cardiac 
tamponade group increased significantly at 240 min, but it was reduced in the treated group 
(cardiac tamponade group: M = 15.01; p25 = 12.56; p75 = 17.56 s vs AcPepA group: M = 
7.65; p25 = 7.33; p75 = 8.67 s). By the end of the experiments, the characteristic variable of 
the mucosal microcirculation, the average RBCV of the flow pattern, was significantly 
reduced in the cardiac tamponade group if compared to the AcPepA group (Figure 2B). 
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Figure 2. Changes in superior mesenteric artery blood flow (A) and average red blood cell velocity (B) in the 
sham-operated (n = 6; solid triangles with continuous line), cardiac tamponade (n = 7; empty squares with solid 
line), and AcPepA-treated (n = 6; empty circles with solid line) groups. The box indicates the duration of the 
cardiac tamponade; the arrow shows the treatment with AcPepA. The plots demonstrate the median values and 
the 25
th
 (lower whisker) and 75
th
 (upper whisker) percentiles; * p < 0.05 within groups versus baseline values 
(Friedman repeated-measures analysis of variance on ranks followed by Dunn’s method), x p < 0.05 between 
groups versus sham-operated group values (Kruskal-Wallis one-way analysis of variance on ranks, followed by 
Dunn’s method), and # p < 0.05 between AcPepA-treated group and cardiac tamponade group (Kruskal-Wallis 
one-way analysis of variance on ranks, followed by Dunn’s method). 
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4.1.2. Acute hemodynamic changes in Study II 
 In these experiments MAP, CO and the SMA flow were monitored to gain information 
about the circulatory changes induced by PAO and to verify the decrease in the SMA flow. 
During PAO, while the MAPF was kept between 30-40 mmHg, the MAPC was significantly 
increased initially compared to both the baseline values of the general MAP and to the MAPC 
values in the sham operated group, however later it was significantly different only from the 
baseline values. The CO started to decrease after 30 min of PAO and reached a significant 
difference compared to the sham operated group and to the baseline values by the end of 
PAO. 
 MAP was significantly increased in 30 min after the relief of PAO and then returned 
gradually to the control values by the end of the observation period. The CO started to 
increase after the PAO and no significant differences could be detected during the post-
occlusion period. The SMA flow decreased significantly during the PAO and remained 
significantly lower compared to the baseline and sham operated values until the end of the 
experiments (Table 2).  
 
 
 
 
MAP during PAO on Day 1 
 Parameters Baseline  
30 min 
(Carotid 
artery) 
60 min 
(Carotid 
artery) 
90 min 120 min 
30 min 
(Femoral 
artery) 
60 min 
(Femoral 
artery) 
       
Sham 
operated 
Median 
25p; 75p 
106.0 
88.9; 111.2 
107.0 
88.9; 119.7 
112.5 
87.63; 122.1 103.5 
86.1; 116.0 
108.2 
67.6; 122.5 105.5 
90.5; 113.3 
109.6 
89.5; 122.0 
       
PAO 
Median 
25p; 75p 
107.5 
99.0; 113.8 
147.0*x 
139.8; 158.8 
133.1* 
121.8; 142.5 128.5*x 
122.0; 135.2 
109.3 
103.4; 119.1 37.5*x 
31.8; 41.3 
37.5*x 
30.7; 41.2 
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CO during PAO on Day 1 
 Parameters Baseline 30 min 60 min 90 min 120 min 
Sham 
operated 
Median 
25p; 75p 
210 
205; 217 
216 
197; 229 
217 
187; 237 
204 
195; 232 
216 
189; 225 
PAO 
Median 
25p; 75p 
206 
200; 214 
206 
181; 250 
164*x 
150; 178 
184 
173; 210 
203 
181; 225 
SMA flow during PAO on Day 1 
 Parameters Baseline 30 min 60 min 90 min 120 min 
Sham 
operated 
Median 
25p; 75p 
14.2 
12.3; 16.0 
14.0 
11.8; 17.0 
14.9 
14.1; 15.8 
14.6 
13.6; 19.7 
15.2 
12.5; 18.6 
PAO 
Median 
25p; 75p 
15.3 
13.8; 15.6 
1.4*x 
1.8; 2.1 
2.1*x 
1.2; 2.6 
10.8*x 
9.2; 12.1 
8.6*x 
8.3; 10.2 
 
Table 2. Changes in MAP [mmHg], CO [mL min
-1
 kg
-1
] and SMA flow [mL min
-1
] on Day 1. * p<0.05 within 
groups vs baseline values (Friedman and Dunn test); 
x
 p<0.05 PAO group vs sham-operated group (Mann-
Whitney and Dunn test). 
 
4.1.3. Hemodynamic changes in Study III  
 In the sham operated animals, there were no significant changes in the MAP on day 1. 
In the groups with PAO, the MAP was kept between 30-40 mmHg for 60 min. The MAP was 
significantly higher in the PAO group compared to the control group 30 min after the relief of 
aorta occlusion. AcPepA treatment did not influence these parameters. No difference was 
found between the groups in the parameters of serosal microcirculation, when measured in the 
control period before PAO (Figure 3A).  
 On day 2, the MAP did not differ between the groups or the baseline values of day 1. 
The surgical interventions caused an increase in HR by day 2. Nonetheless, the HR was 
significantly higher in the PAO group compared to the sham operated animals, while after 
AcPepA treatment, the HR did not increase significantly in respect of the values of the sham 
operated group (Figure 3B). The SMA flow in the treated group remained at the control level, 
while in the non-treated group it was significantly higher in comparison with the sham 
operated group. The elevated CO was significantly decreased following C5a inhibitor 
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treatment on day 2 (Figure 4). On day 2, both the serosal and mucosal RBCV were 
significantly decreased in comparison with the sham operated group. AcPepA treatment 
resulted in a significantly higher RBCV (Figure 5AB).  
 
 
 
Figure 3. Changes in MAP in the sham operated (empty circles with thin continuous line; empty box), PAO 
(black squares with continuous line; gray box) and PAO+AcPepA (empty triangles with continuous line; striped 
empty box) groups (A). The plots demonstrate the median (horizontal line in the box) and the 25
th
 and 75
th
 
percentiles. * p<0.05 within groups vs baseline values, 
x
 p<0.05 between groups vs control group values. 
Changes in heart rate in the control (empty box), PAO (gray box) and PAO+AcPepA (striped empty box) groups 
(B). The plots demonstrate the median (horizontal line in the box) and the 25
th
 and 75
th
 percentiles. * p<0.05 
within groups vs baseline values, 
x
 p<0.05 between groups vs control group values. 
27 
 
 
 
 
 
Figure 4. Changes in CO index (A) and in SMA flow (B) in the sham operated (empty box), PAO (gray box) 
and PAO+AcPepA (striped empty box) groups. The plots demonstrate the median (horizontal line in the box) 
and the 25
th
 and 75
th
 percentiles. 
x
 p<0.05 between groups vs control group values. 
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Figure 5. Changes in serosal (A), mucosal (B) RBCV and plasma ET-1 levels (C) in the sham operated (empty 
box), PAO (gray box) and PAO+AcPepA (striped empty box) groups. The plots demonstrate the median 
(horizontal line in the box) and the 25
th
 and 75
th
 percentiles. 
#
 p<0.05 between AcPepA-treated group vs PAO 
group. 
 
4.1.4. Microvascular and structural damage of the mucosa in Study III, day 2 
 The microvessels in the villi were visualized by FITC-dextran administration, while 
the morphology of the mucosa was examined with acriflavin staining. In the PAO group, the 
CLSEM evaluation demonstrated significant tissue damage in contrast with the sham operated 
group (Figure 6). The vessel structure was disorganized and fluorescent dye leakage could be 
observed. The acriflavin staining of the surface of the villi revealed the presence of 
longitudinal fissure and epithelial gaps and showed large amount of debris (Figure 7 A-C).  
Administration of the C5a inhibitor AcPepA decreased the mucosal damage and 
significantly influenced both the changes in the microvascular structure and in the epithelial 
morphology of the small intestine. These changes were still more prominent than in the sham 
operated group, but the degree of injury was decreased, as shown by the reduced dye leakage 
compared to the non treated PAO group (Figure 7 D-F). 
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Figure 6. Level of mucosal injury manifested by CLSEM in vivo histological records in the sham operated 
(empty box), PAO (gray box) and PAO+AcPepA (striped empty box) groups. The plots demonstrate the median 
(horizontal line in the box) and the 25
th
 and 75
th
 percentiles. 
x
 p<0.05 between groups vs control group values; 
#
 
p<0.05 between AcPepA-treated group and PAO group. 
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Figure 7. In vivo histological (CLSEM) records showing the changes of the epithelial surface 24 hrs after the 
PAO (acriflavin staining) in the sham operated (A), PAO (B) and PAO+AcPepA (C) groups. Alterations in the 
microvascular structure was visualized with CLSEM after iv administration of FITC-dextran in the sham 
operated (D), PAO (E) and PAO+AcPepA (F) groups. 
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4.2. Biochemical parameters  
4.2.1. Changes in biochemical parameters in Study I 
 Peripheral blood samples were taken at baseline, after 75 and 150 min, and at the end 
of the observation period (240 min). big-ET is a stable precursor of ET-1 with a longer half-
life; it is released from different types of cells. The plasma big-ET levels increased 
significantly four- to five-fold in the non-treated group after cardiac tamponade (Figure 8A). 
HMGB-1 is a very effective signal for neutrophil activation, which causes an escalation of the 
inflammatory process. The plasma level of HMGB-1 was elevated significantly after the 
compression of the heart (Figure 8B). The rate of neutrophil accumulation was determined 
with the help of the measurement of MPO activity of the intestinal tissue samples taken at the 
end of the experiments. The level of MPO activity was significantly higher in the small 
intestinal tissue samples of the cardiac tamponade group, indicating the increased 
accumulation of neutrophils (Figure 9A). In the cardiac tamponade group, increased 
superoxide production was perceptible in the blood at the beginning of the post-tamponade 
phase (Figure 9B). After AcPepA administration, the characteristic biochemical changes 
following the cardiac tamponade were significantly different. The AcPepA treatment reduced 
the concentrations of big-ET and HMGB-1 in the plasma. The amount of oxygen free radicals 
that were formed was also reduced by the treatment, and the MPO activity was decreased as 
well (Figures 8-9).  
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Figure 8. Changes in plasma big-endothelin concentration (A), and plasma HMGB-1 level (B) in the sham-
operated (n = 6; solid triangles with continuous line), cardiac tamponade (n = 7; empty squares with solid line), 
and AcPepA-treated (n = 6; empty circles with solid line) groups. The box indicates the duration of the cardiac 
tamponade; the arrow shows the treatment with AcPepA. The plots demonstrate the median values and the 25
th
 
(lower whisker) and 75
th
 (upper whisker) percentiles; * p < 0.05 within groups versus baseline values (Friedman 
test for repeated-measures analysis of variance on ranks followed by Dunn’s method), x p < 0.05 between groups 
vs sham-operated group values (Kruskal-Wallis one-way analysis of variance on ranks, followed by Dunn’s 
method), and 
# 
p < 0.05 between AcPepA-treated group vs cardiac tamponade group (Kruskal-Wallis one-way 
analysis of variance on ranks, followed by Dunn’s method). 
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Figure 9. Changes in small intestinal MPO activity (A) in the sham-operated (n = 6; empty box), cardiac 
tamponade (n = 7; striped box), and AcPepA-treated (n = 6; checked box) groups. Changes in whole blood 
superoxide production (B) in the sham-operated (n = 6; solid triangles with continuous line), cardiac tamponade 
(n = 7; empty squares with solid line) and AcPepA-treated (n = 6; empty circles with solid line) groups. The box 
indicates the duration of the cardiac tamponade; the arrow shows the treatment with AcPepA. The plots 
demonstrate the median (horizontal line in the box) and the 25
th
 and 75
th
 percentiles. * p < 0.05 within groups 
versus baseline values (Friedman test for repeated-measures analysis of variance on ranks followed by Dunn’s 
method), 
x
 p < 0.05 between groups vs sham-operated group values (Kruskal-Wallis one-way analysis of 
variance on ranks, followed by Dunn’s method), and # p < 0.05 between AcPepA-treated group vs cardiac 
tamponade group values (Kruskal-Wallis one-way analysis of variance on ranks, followed by Dunn’s method). 
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4.2.2. Changes in biochemical parameters in Study II-III 
 The concentrations of inflammatory mediators TNF-α and HMGB1 were increased 
significantly 24 hrs following the ischemic insult. The C5a inhibitor treatment decreased the 
level of TNF-α, similarly to the concentration of HMGB-1 (Figure 10AB). The level of ET-1, 
an important vasoconstrictor, which can be responsible for the impairment of the mucosal 
microcirculation, was also elevated on the day after the PAO (Figure 5C). The administration 
of AcPepA was able to decrease the ET-1 concentration significantly.  
 On the second day of the experiments, significant leukocyte accumulation was 
observed in the PAO group as compared to the sham operated animals. The administration of 
AcPepA significantly reduced the leukocyte infiltration of the small intestinal wall (Figure 
10C).  
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Figure 10. Changes in plasma TNF-α (A), HMGB-1 (B) levels and small intestinal leukocyte infiltration (C) in 
the sham operated (empty box), PAO (gray box) and PAO+AcPepA (striped empty box) groups. The plots 
demonstrate the median (horizontal line in the box) and the 25
th
 and 75
th
 percentiles. 
x
 p<0.05 between groups vs 
control group values; 
#
 p<0.05 between AcPepA-treated group and PAO group. 
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5. DISCUSSION 
5.1. Acute circulatory and inflammatory consequences of experimental cardiac tamponade 
and complement C5A antagonist treatment: Study I 
 We have characterized the acute hemodynamic consequences of temporary mechanical 
compression of the heart. In this setup we have also outlined the consequences of C5a 
antagonism on the early splanchnic circulatory changes. In this porcine model, the post-
tamponade period was characterized by decreased MAP and CVP, whereas the HR was 
significantly elevated. These acute hemodynamic alterations were accompanied by definite 
signs of inflammatory activation, with the release of vasoactive and proinflammatory 
mediators, including histamine, HMGB-1, and big-ET. The deterioration of the systemic 
circulation was followed by parallel impairment of the microcirculation in the splanchnic 
area. These changes were accompanied by an increase in local MPO activity, a quantitative 
marker of ROS-producing neutrophils in the plasma and various tissues (69, 70). 
 After the relief of the cardiac tamponade, the MAP was decreased, whereas the CO 
remained compensated, and there were no significant differences if compared to the control 
group. This was achieved by the elevated HR, which refers to the increased strain of the heart 
muscle. Following AcPepA treatment, the MAP was elevated compared to the control level 
and the CO was also maintained. Thus, the most pronounced differences between the 
compensating mechanisms of treated and non-treated tamponade groups were the restored CO 
and the lower HR. This seems to be especially crucial if we consider the fact that the 
circulation of the heart muscle is supplied during the diastolic phase, and it nearly stops 
during the systole. If the HR is increased, the length of the systole does not change, while the 
diastole is shortened. A higher frequency results in less time for oxygen delivery to the 
cardiac muscle cells, and therefore a lower HR and maintained CO provide better oxygenation 
for the heart. The elevated CVP in the treated group also indicate that the main compensatory 
mechanism in this early phase is switched from an increased afterload to an elevation of the 
preload. These changes might be the consequences of reduced ET and histamine release after 
AcPepA treatment. Indeed, it has been shown that non-selective ET-receptor antagonism 
increases the CO and decreases the peripheral resistance in patients with congestive heart 
failure (71). On the contrary, C5a causes histamine release from mast cells, which may lead to 
enhanced vascular permeability and a relative blood loss into the dilated vessels. The 
38 
 
 
 
elevation in plasma histamine level in the early post-tamponade phase, together with previous 
data, shows that this level is higher in the portal venous blood than that in the arterial blood 
(14). In the presence of AcPepA, the histamine release was reduced, and this effect can also 
contribute to the increased venous return.  
 In this porcine model, the pericardial tamponade triggered characteristic macro- and 
microcirculatory changes in the bowels. The share of the splanchnic area from the reduced 
CO was diminished during the tamponade, but the SMA flow, which reflects the blood supply 
of the small intestine and colon, was restored thereafter, and no differences were observed 
compared to the sham-operated group. Nevertheless, in the AcPepA-treated group, the SMA 
flow was significantly elevated at the beginning of the post tamponade phase, and gradually 
returned to the control level by the end of the experiments. This early flow elevation may be 
attributable to the relative lack of vasoconstrictor ET-1 effects because it has been 
demonstrated that ET-A receptor inhibition is able to improve the splanchnic circulation in 
similar cases (25).  
 In shock conditions, an important feature of the splanchnic microcirculatory 
disturbances is heterogeneity, which worsens the oxygen supply and metabolism of the cells 
(72, 73). A heterogeneously oscillating microcirculation can be well characterized by the 
average RBCV (68, 74). It has been demonstrated that the duration of the high-flow 
component of a heterogeneous microcirculation is increased significantly following ET-A 
receptor inhibition (68). From this point of view, the excessive release of ET-1 can be an 
important part of the worsening of inflammatory responses, when intensive complement 
activation is present. ET-1 release can contribute to the impairment of the microcirculation 
and, due to its vasoconstrictor effects, to the changes in the macrohemodynamics throughout 
such conditions, and it can even influence the pattern of cytokine release (75).  
 The cause of the improved mucosal RBCV in the AcPepA-treated group may be 
multifactorial. The decreased levels of ET-1 formation and leukocyte activation each can 
effectively reduce the extent of intermediate reactive oxygen formation. By the reduction of 
these sources of tissue damage, the endothelial function can be preserved, which subsequently 
results in the improvement of microcirculation. 
 We found increased HMGB-1 levels after tamponade, which were significantly 
reduced by AcPepA treatment. These findings correlate to the similar results of continuous 
AcPepA treatment in a primate endotoxin shock model (50).  
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 These results can be explained by the involvement of the C5L2 receptor, a high-
affinity C5a receptor, which was earlier thought to be a non-signaling, scavenger receptor of 
C5a as it is incapable of G-protein coupling. Recent findings, however, have proved that 
C5L2 has a more important role in mediating inflammatory responses of the innate immune 
system. The survival rate in C5L2 knockout mice was increased after cecal ligation and 
puncture–induced sepsis in relation to the survival rate in wild-type mice and it has been 
described that the release of the potent proinflammatory cytokine HMGB-1 after endotoxin + 
C5a or only endotoxin administration was diminished in C5L2 knockout macrophages (45). 
 To determine the effects that can be linked to C5a antagonist treatment, we had to 
consider and rule out artificial influences that may originate from the experimental design. 
We, therefore, applied standard fluid replacement therapy in all groups to exclude the effects 
of the volume status on the microcirculation. The clinical limitations are evident, but it is very 
likely that a preserved microcirculatory function in the GI tract is mediated directly or 
indirectly by C5a pathways in this experimental NOMI model of anesthetized, ventilated, and 
thoracotomized minipigs. 
 In conclusion, these results demonstrated the emergence of NOMI among the acute 
circulatory complications of cardiac tamponade, and the potential role of C5a antagonism in 
reducing signals that are important components in the development of a secondary splanchnic 
microcirculatory disturbance. 
 
5.2. Late hemodynamic and inflammatory consequences of NOMI in rats. Study II-III 
 We have designed an animal model in which the main clinical features of NOMI are 
reproducible. Key elements are persistently decreased SMA flow after an extramesenteric 
insult and the reduced invasiveness, which makes the long-term observations possible. In this 
context we have obtained conclusive evidences for the significantly diminished SMA blood 
flow after partial occlusion of the subdiaphragmatic aorta, which persisted during the 24 hour 
post-occlusion period, despite the compensated CO and MAP (see Table 2). It should be 
added that the late hemodynamic changes were characteristic to a systemic inflammatory 
response syndrome. Although MAP was in the normal range, the HR and CO was 
significantly increased, as part of the compensatory mechanism. During the early phase of 
systemic inflammation, the oxygen demand is increased due to the high metabolic rate. To 
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meet this need, oxygen delivery is increased mostly through the elevation of CO. 
Nevertheless, the oxygenation of the cells cannot be improved without a properly functioning 
microcirculation, and a deterioration of capillary perfusion will prevent the oxygen 
consumption despite the seemingly increased delivery. In our model the small intestinal 
microcirculation was significantly impaired 24 hours following the insult as shown by the 
decreased RBCV at both serosal and mucosal surfaces. This means that microcirculatory 
damage was present in the gastrointestinal wall despite of the normal or increased SMA flow 
(76).  
 Nevertheless, it is important to note some limitations of the experimental model. One 
of these is the significantly increased MAP that can evolve above the site of the aorta 
occlusion. It can approximate the upper limits of the cerebral autoregulation (77) for a short 
period, during the first 30 min of the PAO. However, the manoeuvre is tolerable, since no 
animals were lost during the first 24 hours and none of them showed any signs of injury of the 
central nervous system. The other problem is the need for invasive blood pressure 
measurement in the femoral artery because it provides more precise data for the adjustment of 
PAO as compared with the non-invasive possibilities. During the design of the model we took 
in consideration that well-developed collateral vascularization in the rat hind limb can provide 
adequate tissue perfusion even after the ligation of the femoral artery (78, 79). Nevertheless, 
before the recovery period, the animals were observed and in case of any signs of permanent 
hind limb ischemia, like cyanosis, stiffness, the experiment was terminated and the animals 
were excluded from the study. The low number of such animals (n=3) suggests that the 
ligation of the femoral artery could be possible in these studies. 
 In this setup we have administered AcPepA, a synthetic, antisense C5a inhibitor 
compound. In the AcPepA-treated group, the small intestinal RBCV was significantly higher 
on day 2, and the improved microcirculation was present without an increase in CO and SMA 
flow which may refer to the better efficacy of oxygen extraction. 
 The decreased ET-1 level after AcPepA treatment may have contributed to the 
improvement of the small intestinal microcirculation, and the altered proinflammatory 
cytokine profile may also refer to a reduced inflammatory activation as a consequence of C5a 
inhibitor therapy. ET-1 is one of the most important vasoconstrictive factors in the splanchnic 
microcirculation, and it has been shown that administration of selective ET-A receptor 
antagonist significantly improves the small intestinal microcirculation in lowflow conditions 
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(68). More importantly, the excessive release of ET-1 enhances leukocyte activation in the 
postcapillary venules of the small intestine (44) which may further increase the local tissue 
damage.  
 The increased circulatory HMGB-1 and TNF-α levels are another important features 
of our model, and these findings are in concordance with the clinical observations (80). High 
level of TNF-α can directly impair gastrointestinal epithelial tight junctions (81), thus a 
decreased level of TNF-α in the AcPepA-treated group may not only be a direct sign of the 
alleviated inflammatory cascade activation, but may be indirectly associated with the 
preservation of the barrier function. Similarly, an increased HMGB-1 output can amplify the 
inflammatory signals and a significant decrease in the HMGB-1 level may be the key sign of 
decreased systemic inflammatory response (82). HMGB-1 is a highly potent alarming signal 
originating from necrotic cells or actively released from immune cells, and it causes leukocyte 
recruitment and the release of other inflammatory cytokines (46). The release is directly 
mediated by C5a through C5L2 receptors and the blockade or absence of C5L2 receptors 
improves the survival in murine sepsis (45). The net result of a diminished HMGB-1 and 
TNF-α release is the reduced leukocyte accumulation. This was verified by traditional 
histology: leukocyte infiltration was significantly lower in the small intestinal wall in the 
AcPepA-treated group. All these macro-, microcirculatory and inflammatory effects of PAO 
culminated in visible damage of the mucosa (see Figure 5), and C5a inhibition that resulted in 
a significant decrease in tissue damage, preserved villus structure and microvascular 
architecture was demonstrated by in vivo histology as well.  
 In summary, we have characterized some of the potentially detrimental circulatory and 
proinflammatory consequences of non-occlusive mesenteric hypoperfusion in a novel rodent 
model. In this experimental setup, a single iv dose of complement C5a antagonist AcPepA 
compound was suitable for improving the local circulatory changes and it reduced the 
secondary mucosal damage in a relatively wide time frame, at least 24 hours after the insult. 
The human relevance of these data is still unknown, but the approach holds promise for future 
use in NOMI-associated situations. 
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6. SUMMARY OF NEW FINDINGS 
 
 Experimental pericardial tamponade causes systemic inflammation and diminished 
microcirculation in the splanchnic area, and this provides opportunity to study the 
pathophysiology of NOMI in a large animal model. 
 Complement C5a antagonist treatment with AcPepA improves the splanchnic 
microcirculation and reduces the acute inflammatory consequences of pericardial 
tamponade, thus complement activation can play a role in the short-term microcirculatory 
disturbances of NOMI. 
 We have developed and characterized a new rodent model of partial aorta occlusion, 
and adapted it to the investigation of the long-term hemodynamic and inflammatory 
consequences of experimental NOMI in a clinically relevant time frame. 
 Experimental NOMI diminishes the microcirculation within the intestinal wall and 
causes inflammatory activation and secondary mucosal damage. The complement C5a 
antagonist AcPepA treatment is competent to improve the microcirculation and reduces the 
inflammatory activation, which suggests that complement activation plays a central role 
also in the late, potentially damaging consequences of NOMI. 
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